
Why does a standard immunotherapy work remarkably well for some bladder cancer patients, but fail for others? In this episode, Northwestern Medicine physician-scientist Joshua Meeks, MD, PhD, breaks down his recent research published in the Journal of Clinical Investigation and European Urology uncovering how the tumor microenvironment and immune cellular communication influence response to Bacillus Calmette-Guérin (BCG) immunotherapy. Find out how single-cell RNA sequencing, macrophage–T-cell interactions, and urinary tumor DNA biomarkers are paving the way for targeted, personalized bladder cancer care.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Rewind: What Determines Who Gets a Transplant? with Daniela Ladner, MD, MPH

Rewind: Decoding Metabolism and Why When You Eat Matters with Joseph Bass, MD, PhD

How Our Genes Predispose Us to Infection with Jean-Laurent Casanova, MD, PhD

Why It's Important to Analyze Research Data by Sex with Nicole Woitowich, PhD
Free AI-powered recaps of Breakthroughs and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.